The decision to perform medical imaging is based on clinical reasoning, that is, the medical history, symptoms, and findings on physical examination, followed by an assessment of clinical probability. Probability testing
The most commonly used method to predict clinical probability, the Wells score, is a clinical prediction rule, whose use is complicated by multiple versions being available. In 1995, Philip Steven Wells, initially developed a prediction rule (based on a literature search) to predict the likelihood of PE, based on clinical criteria. The prediction rule was revised in 1998 This prediction rule was further revised when simplified during a validation by Wells et al. in 2000. In the 2000 publication, Wells proposed two different scoring systems using cutoffs of 2 or 4 with the same prediction rule. In 2001, Wells published results using the more conservative cutoff of 2 to create three categories. An additional version, the "modified extended version", using the more recent cutoff of 2 but including findings from Wellss initial studies were proposed. Most recently, a further study reverted to Wellss earlier use of a cutoff of 4 points to create only two categories.There are additional prediction rules for PE, such as the Geneva rule.
Yao syndrome (YAOS) (formerly called NOD2-associated autoinflammatory disease) is an autoinflammatory syndrome involving episodes of fever and abnormal inflammation affecting many parts of the body, particularly the skin, joints, and gastrointestinal system. Signs and symptoms
Arthralgia (Arthritis)
Fever
Diarrhea
Abdominal Pain
Keratoconjunctivitis Sicca (Dry eyes)
Pleurisy
Idiopathic Pericarditis
Xerostomia (Dry mouth)
Erythematous Plaques
Dermatitis

Diagnostic criteria
Yao syndrome is diagnosed if 2 major criteria, at least one minor criterion, the molecular criterion, and exclusion criteria are fulfilled. Treatment
A study to determine the effectiveness of Novartis pharmaceutical drug Canakinumab was conducted. In this study, canakinumab was effective in patients with YAOS, and thus clinical trial of canakinumab may be warranted as a therapeutic option for this disease. Inheritance
Yao Syndrome inheritance is classified as Multifactorial Inheritance. References
External links

MedGen-Yao Syndrome
Genetics Home Reference-Yao Syndrome